Developemental Research Program

发展研究计划

基本信息

  • 批准号:
    7246860
  • 负责人:
  • 金额:
    $ 9.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-07-01 至 2012-06-30
  • 项目状态:
    已结题

项目摘要

1. Describe the process used by the SPORE for identifying and selectively funding innovative pilot studies within and outside of the SPORE institution Bert Vogelstein, MD, will continue to serve as Principal Investigator of this Program. The Program has been a major focus of the SPORE because it provides for a continuous flow of innovative ideas and activity to stimulate investigation in the context of SPORE translational research. The Developmental Research Program provides a means to respond to new opportunities, and is designed to encourage and facilitate new research efforts. The Program takes advantage of the broad expertise of researchers at The Johns Hopkins University and of external investigators by providing funds for pilot projects with potential for development into full-fledged translational research avenues, collaborations, and new methodologies for integration into other Research Projects. In most prior years, the Cancer Center has augmented the funding provided to each of our pilot project recipients by approximately 50% per award (on average). In the past two years, the formation of a Gl Cancer program within the Oncology Center has also provided support for additional basic and clinical pilot projects that are not intended to be as translational as the goals of the SPORE Developmental Projects. Within this year, we also have gained a commitment for an additional two pancreatic cancer pilot projects to be funded by institutional sources each year. These resources, and funding pressures from a reduced overall budget for the proposed SPORE funding period, have allowed us to shift some of the financial sources from the SPORE to the institution, as reflected in the newly proposed Developmental Research Budget. 2. Provide a summary identifying the achievements of all projects supported during the last project period. Specifically discuss whether they were promoted to a full project in the SPORE, led to other grant applications, or were terminated because of lack of success. For ongoing activities during the past 12 months, report on progress 3. Provide brief examples of projects that may be supported during the grant period. It seems premature to speculate on projects that may be supported in the distant future. Good ideas for pilot projects should ideally find a source of initial support within a 6-month period, and at most by one year. In our current solicitation, we have favorably evaluated a proposal from Dr. Eshleman to extend his pilot project for a second year to begin July 2006. We are also considering a new proposal to test a nonabsorbable, orally administered antiproliferative agent in patients having had colectomy for Familial Adenomatous Polyposis. 4. Provide a description of the process by which projects will be (or have been) promoted to full translational research projects within the SPORE. Two of the past pilot projects were elevated to the status of Research Project, and two became subjects of SPORE clinical supplemental grants. Elevation to the status of Research Project occurs when a budgetary opportunity occasions a solicitation for new Research Project(s) in the SPORE; thus, the Pilot is required to out-compete all other alternative projects if it is to become a Research Project. In other words, a successful pilot can be a means to prepare an application for the SPORE, and the Developmental Research Program remains keenly aware that a successful pilot program can be a potent source of rejuvenation for the SPORE. Budgetary openings represent a limited window of opportunity, and thus a second pathway has also been made available, which is to incorporate the best directions of our pilots into our ongoing Research Projects or into our Cores. It is by this method that the cytogenetics project of Dr. Griffin became a component of our Tissue Core for a number of years, that the studies Dr. Maitra became associated with the current Project 2A (which is the proposed Project 3C, to be co-led by Dr. Maitra), and that the studies of Dr. Pandey became associated with the proposed project 3B.
1.描述SPORE用于识别和选择性资助创新试点的流程 在SPORE机构内外进行研究 Bert Vogelstein博士将继续担任该项目的主要研究员。该方案是一个 SPORE的主要重点,因为它提供了创新思想和活动的持续流动, 在SPORE转化研究的背景下激发调查。发展研究计划 提供了一种应对新机遇的手段,旨在鼓励和促进新的研究 努力该计划利用了约翰霍普金斯大学研究人员的广泛专业知识 和外部调查员,为有可能发展成为正式调查员的试点项目提供资金, 转化研究途径,合作,以及融入其他研究的新方法 项目在过去的几年里,癌症中心增加了对我们每个试点项目的资助。 每个奖项的获奖者约占50%(平均)。在过去的两年里, 肿瘤中心的癌症项目还为额外的基础和临床试点项目提供了支持。 不打算像SPORE开发项目的目标那样具有转化性的项目。内 今年,我们还获得了另外两个胰腺癌试点项目的承诺, 每年都有机构资助。这些资源和资金压力从整体上减少 预算为拟议的SPORE资金期间,使我们能够转移一些财政来源, 该机构的SPORE,反映在新提出的发展研究预算。 2.提供一份总结,说明在上一个项目期间支持的所有项目的成就 期具体讨论他们是否被提升为一个完整的项目在SPORE,导致其他 补助金申请,或因不成功而被终止。在联合国大会期间正在进行的活动 过去12个月的进展情况报告 3.提供在资助期内可能获得资助的项目的简要例子。 现在推测在遥远的将来可能得到支持的项目似乎为时过早。飞行员的好主意 理想的情况是,项目应在6个月内,最多在一年内找到初步支助来源。在我们 目前的招标,我们已经积极评价了Eshleman博士的建议,以延长他的试点项目, 第二年至2006年7月开始。我们还在考虑一项新的建议, 在因家族性腺瘤性息肉病行结肠切除术的患者中给予抗增殖剂。 4.提供项目将(或已经)提升到全面的过程描述 SPORE内的翻译研究项目。 过去的两个试点项目被提升为研究项目,两个项目成为 SPORE临床补充补助金。研究项目地位的提升发生在预算 机会在SPORE中征集新的研究项目;因此,飞行员需要 如果它要成为一个研究项目,就必须超越所有其他的替代项目。换句话说,成功的 试点可以是一种手段,准备申请的SPORE,和发展研究计划 仍然敏锐地意识到,一个成功的试点计划可以是一个强大的来源振兴的孢子。 预算缺口是一个有限的机会之窗,因此, 提供,这是把我们的飞行员的最佳方向纳入我们正在进行的研究项目,或 我们的核心正是通过这种方法,格里芬博士的细胞遗传学项目成为我们的一个组成部分。 多年来,Maitra博士的研究与当前的项目2A相关 (这是拟议的项目3C,由Maitra博士共同领导),Pandey博士的研究成为 与拟议项目3B有关。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bert Vogelstein其他文献

Bert Vogelstein的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bert Vogelstein', 18)}}的其他基金

Molecular Genetic Analysis of Colorectal Cancer
结直肠癌的分子遗传学分析
  • 批准号:
    7911315
  • 财政年份:
    2009
  • 资助金额:
    $ 9.51万
  • 项目类别:
ANIMAL RESOURCES
动物资源
  • 批准号:
    7304670
  • 财政年份:
    2006
  • 资助金额:
    $ 9.51万
  • 项目类别:
Developmental Research Program
发展研究计划
  • 批准号:
    7212438
  • 财政年份:
    2006
  • 资助金额:
    $ 9.51万
  • 项目类别:
Developmental Research Program
发展研究计划
  • 批准号:
    10246372
  • 财政年份:
    1997
  • 资助金额:
    $ 9.51万
  • 项目类别:
Developmental Research Program
发展研究计划
  • 批准号:
    10006166
  • 财政年份:
    1997
  • 资助金额:
    $ 9.51万
  • 项目类别:
Developmental Program
发展计划
  • 批准号:
    8366127
  • 财政年份:
    1997
  • 资助金额:
    $ 9.51万
  • 项目类别:
P53 GENE IN HUMAN NEOPLASIA
人类肿瘤中的 P53 基因
  • 批准号:
    2091181
  • 财政年份:
    1983
  • 资助金额:
    $ 9.51万
  • 项目类别:
MOLECULAR GENETIC ANALYSIS OF COLORECTAL CANCER
结直肠癌的分子遗传学分析
  • 批准号:
    6124579
  • 财政年份:
    1983
  • 资助金额:
    $ 9.51万
  • 项目类别:
CLONAL ANALYSIS OF HUMAN NEOPLASIA
人类肿瘤的克隆分析
  • 批准号:
    3482315
  • 财政年份:
    1983
  • 资助金额:
    $ 9.51万
  • 项目类别:
CLONAL ANALYSIS OF HUMAN NEOPLASIA
人类肿瘤的克隆分析
  • 批准号:
    3482318
  • 财政年份:
    1983
  • 资助金额:
    $ 9.51万
  • 项目类别:

相似海外基金

Roles for Adenomatous polyposis coli in colon injury prevention and wound healing
腺瘤性大肠杆菌在预防结肠损伤和伤口愈合中的作用
  • 批准号:
    10707443
  • 财政年份:
    2022
  • 资助金额:
    $ 9.51万
  • 项目类别:
Inhibition of the Wnt Receptor Complex by the Tumor Suppressor Adenomatous Polyposis Coli
抑癌基因腺瘤性息肉病大肠杆菌对 Wnt 受体复合物的抑制
  • 批准号:
    10063347
  • 财政年份:
    2020
  • 资助金额:
    $ 9.51万
  • 项目类别:
Inhibition of the Wnt Receptor Complex by the Tumor Suppressor Adenomatous Polyposis Coli
抑癌基因腺瘤性息肉病大肠杆菌对 Wnt 受体复合物的抑制
  • 批准号:
    10217057
  • 财政年份:
    2020
  • 资助金额:
    $ 9.51万
  • 项目类别:
Inhibition of the Wnt Receptor Complex by the Tumor Suppressor Adenomatous Polyposis Coli
抑癌基因腺瘤性息肉病大肠杆菌对 Wnt 受体复合物的抑制
  • 批准号:
    10653134
  • 财政年份:
    2020
  • 资助金额:
    $ 9.51万
  • 项目类别:
Inhibition of the Wnt Receptor Complex by the Tumor Suppressor Adenomatous Polyposis Coli
抑癌基因腺瘤性息肉病大肠杆菌对 Wnt 受体复合物的抑制
  • 批准号:
    10424450
  • 财政年份:
    2020
  • 资助金额:
    $ 9.51万
  • 项目类别:
The molecular mechanism of adenomatous polyposis coli-binding protein EB1 in HCC
腺瘤性息肉病大肠杆菌结合蛋白EB1在肝癌中的分子机制
  • 批准号:
    25430134
  • 财政年份:
    2013
  • 资助金额:
    $ 9.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Expressioon of Adenomatous Polyposis Coli protein in the mouse cochlea.
腺瘤性息肉病大肠杆菌蛋白在小鼠耳蜗中的表达。
  • 批准号:
    24592538
  • 财政年份:
    2012
  • 资助金额:
    $ 9.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Tumor suppressor adenomatous polyposis coli and breast carcinogenesis
抑癌性腺瘤性结肠息肉病与乳腺癌发生
  • 批准号:
    7234812
  • 财政年份:
    2003
  • 资助金额:
    $ 9.51万
  • 项目类别:
Inactivation model of human Adenomatous Polyposis Coli gene by using budding yeast in vivo.
利用芽殖酵母体内的人腺瘤性息肉病大肠杆菌基因失活模型。
  • 批准号:
    10470129
  • 财政年份:
    1998
  • 资助金额:
    $ 9.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B).
Immunohistochemical and molecular biological study on abnormality of adenomatous polyposis coli gene in oral cancer and premalignant lesion.
口腔癌及癌前病变中腺瘤性息肉病基因异常的免疫组织化学和分子生物学研究。
  • 批准号:
    07671962
  • 财政年份:
    1995
  • 资助金额:
    $ 9.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了